Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Digital breast tomosythesis now makes up close to 50% of mammography systems in the U.S. "Tomo is going to replace just straight digital mammography simply because of the benefit of fewer recalls," explained Debra L. Monticciolo, MD.
Himanshu Gupta, MD, says the implementation of FFR-CT at his facility has provided significant value. He and his colleagues are even working to explore additional ways the technology can help them improve patient care.
Nasir Siddiqui, MD, chair of radiology at Duly Health and Care, explains how the suburban Chicago company uses computed tomography to more effectively treat its customers.
Renee Bullock-Palmer, MD, director, non-invasive cardiac imaging, at the Deborah Heart and Lung Center, explains CT calcium scoring can determine if a patient needs to take aspirin and statins for prevention of coronary disease.
Rad Partners' Nina Kottler, MD, explains what practices should consider when assessing artificial intelligence solutions in an era where there is little reimbursement.
Michael Bruno, MD, vice chair for quality and patient safety at the Penn State Milton S. Hershey Medical Center, discusses two hot topics at RSNA 2023.
The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.
GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview.
Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.
